Celldex Therapeutics Price to Free Cash Flow Ratio 2010-2022 | CLDX

Historical price to free cash flow ratio values for Celldex Therapeutics (CLDX) since 2010. For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Celldex Therapeutics Price to Free Cash Flow Ratio Historical Data
Date Stock Price TTM FCF per Share Price to FCF Ratio
2023-03-24 36.56 0.00
2022-12-31 44.57 $-2.25 0.00
2022-09-30 28.11 $-2.19 0.00
2022-06-30 26.96 $-1.70 0.00
2022-03-31 34.06 $-1.52 0.00
2021-12-31 38.64 $-1.45 0.00
2021-09-30 53.99 $-1.52 0.00
2021-06-30 33.44 $-1.08 0.00
2021-03-31 20.60 $-1.17 0.00
2020-12-31 17.52 $-1.41 0.00
2020-09-30 14.83 $-1.82 0.00
2020-06-30 13.00 $-2.58 0.00
2020-03-31 1.66 $-2.87 0.00
2019-12-31 2.23 $-3.25 0.00
2019-09-30 2.13 $-4.10 0.00
2019-06-30 2.68 $-4.34 0.00
2019-03-31 4.92 $-5.32 0.00
2018-12-31 2.97 $-7.25 0.00
2018-09-30 6.77 $-7.89 0.00
2018-06-30 7.55 $-9.68 0.00
2018-03-31 34.95 $-10.53 0.00
2017-12-31 42.60 $-11.87 0.00
2017-09-30 42.90 $-12.47 0.00
2017-06-30 37.05 $-13.35 0.00
2017-03-31 54.15 $-16.08 0.00
2016-12-31 53.10 $-17.11 0.00
2016-09-30 60.60 $-16.52 0.00
2016-06-30 65.85 $-17.45 0.00
2016-03-31 56.70 $-15.87 0.00
2015-12-31 235.20 $-16.03 0.00
2015-09-30 158.10 $-17.38 0.00
2015-06-30 378.30 $-17.53 0.00
2015-03-31 418.05 $-17.50 0.00
2014-12-31 273.75 $-17.35 0.00
2014-09-30 194.40 $-17.00 0.00
2014-06-30 244.80 $-15.84 0.00
2014-03-31 265.05 $-15.38 0.00
2013-12-31 363.15 $-13.51 0.00
2013-09-30 531.45 $-13.87 0.00
2013-06-30 234.15 $-13.15 0.00
2013-03-31 173.70 $-12.41 0.00
2012-12-31 100.65 $-12.95 0.00
2012-09-30 94.50 $-13.84 0.00
2012-06-30 77.63 $-12.82 0.00
2012-03-31 76.35 $-13.55 0.00
2011-12-31 39.00 $-13.70 0.00
2011-09-30 34.28 $-12.09 0.00
2011-06-30 53.25 $-14.26 0.00
2011-03-31 60.30 $-15.99 0.00
2010-12-31 61.80 $-15.24 0.00
2010-09-30 60.00 $-16.97 0.00
2010-06-30 68.40 $-18.40 0.00
2010-03-31 92.10 $-21.22 0.00
2009-12-31 70.05 $-22.35 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.714B $0.002B
CELLDEX THERAPEUTICS is an integrated biopharmaceutical company that applies its comprehensive Precision Targeted Immunotherapy Platform to generate a pipeline of candidates to treat cancer and other difficult-to-treat diseases. Celldex's immunotherapy platform includes a complementary portfolio of monoclonal antibodies, antibody-targeted vaccines and immunomodulators to create novel disease-specific drug candidates.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $141.122B 8.73
GSK (GSK) United Kingdom $75.233B 9.43
Bio-Rad Laboratories (BIO.B) United States $13.735B 32.61
QIAGEN (QGEN) Netherlands $10.461B 19.38
Ginkgo Bioworks Holdings (DNA) United States $2.529B 0.00
Arcus Biosciences (RCUS) United States $1.165B 0.00
Biohaven (BHVN) United States $0.882B 0.00
Emergent Biosolutions (EBS) United States $0.391B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.153B 0.00
Enzo Biochem (ENZ) United States $0.102B 0.00
SQZ Biotechnologies (SQZ) United States $0.018B 0.00
Gelesis Holdings (GLS) United States $0.011B 0.00